Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NXN-462 in Post-Herpetic Neuralgia
NCT01748877Phase 2Completed
- Sponsor
- NeurAxon Inc.
- Start
- Jan 2013
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of NXN-462 in postherpetic neuralgia (PHN), sponsored by NeurAxon Inc.. Started Jan 2013; status: completed.
02
Drugs
NXN-462
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on NCT01748877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01748877.